New Once-Daily HIV Oral Alternative Advances New Once-Daily HIV Oral Alternative Advances

The single-pill combination of bictegravir-lenacapavir shows good virologic suppression and tolerability in a 2-year clinical trial; about 8% of people with HIV are still on complex regimens.Medscape Medical News
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: HIV/AIDS Source Type: news